BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 24708398)

  • 1. Metabolic syndrome: a multifaceted risk factor for kidney stones.
    Domingos F; Serra A
    Scand J Urol; 2014 Oct; 48(5):414-9. PubMed ID: 24708398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic syndrome and urinary stone composition: what factors matter most?
    Kadlec AO; Greco K; Fridirici ZC; Hart ST; Vellos T; Turk TM
    Urology; 2012 Oct; 80(4):805-10. PubMed ID: 22795374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metabolic syndrome and nephrolithiasis].
    Kohjimoto Y; Iba A; Sasaki Y; Hara I
    Hinyokika Kiyo; 2011 Jan; 57(1):43-7. PubMed ID: 21304261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney stones: Composition, frequency and relation to metabolic diagnosis.
    Spivacow FR; Del Valle EE; Lores E; Rey PG
    Medicina (B Aires); 2016; 76(6):343-348. PubMed ID: 27959841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
    Hess B
    Ther Umsch; 2003 Feb; 60(2):79-87. PubMed ID: 12649986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of visceral fat area and other metabolic parameters on stone composition in patients undergoing percutaneous nephrolithotomy.
    Zhou T; Watts K; Agalliu I; DiVito J; Hoenig DM
    J Urol; 2013 Oct; 190(4):1416-20. PubMed ID: 23685097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance.
    Abate N; Chandalia M; Cabo-Chan AV; Moe OW; Sakhaee K
    Kidney Int; 2004 Feb; 65(2):386-92. PubMed ID: 14717908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epidemiology of nephrolithiasis in France].
    Daudon M
    Ann Urol (Paris); 2005 Dec; 39(6):209-31. PubMed ID: 16425740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathophysiology, diagnosis and conservative therapy of non-calcium kidney calculi].
    Hochreiter W; Knoll T; Hess B
    Ther Umsch; 2003 Feb; 60(2):89-97. PubMed ID: 12649987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome and uric acid nephrolithiasis.
    Sakhaee K; Maalouf NM
    Semin Nephrol; 2008 Mar; 28(2):174-80. PubMed ID: 18359398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of renal papillae in kidney stone formers.
    Marien TP; Miller NL
    Minerva Urol Nefrol; 2016 Dec; 68(6):496-515. PubMed ID: 27441596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypocitraturia as a pathogenic risk factor in the mixed (calcium oxalate/uric acid) renal stones.
    Alvarez Arroyo MV; Traba ML; Rapado A
    Urol Int; 1992; 48(3):342-6. PubMed ID: 1589930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of formation of human calcium oxalate renal stones on Randall's plaque.
    Evan AP; Coe FL; Lingeman JE; Shao Y; Sommer AJ; Bledsoe SB; Anderson JC; Worcester EM
    Anat Rec (Hoboken); 2007 Oct; 290(10):1315-23. PubMed ID: 17724713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 diabetes increases the risk for uric acid stones.
    Daudon M; Traxer O; Conort P; Lacour B; Jungers P
    J Am Soc Nephrol; 2006 Jul; 17(7):2026-33. PubMed ID: 16775030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of metabolic syndrome traits and severity of kidney stones: results from a nationwide survey on urolithiasis in Japan.
    Kohjimoto Y; Sasaki Y; Iguchi M; Matsumura N; Inagaki T; Hara I
    Am J Kidney Dis; 2013 Jun; 61(6):923-9. PubMed ID: 23433467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteome of human calcium kidney stones.
    Canales BK; Anderson L; Higgins L; Ensrud-Bowlin K; Roberts KP; Wu B; Kim IW; Monga M
    Urology; 2010 Oct; 76(4):1017.e13-20. PubMed ID: 20709378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Who makes uric acid stones and why--observations from a renal stones clinic.
    Stansbridge EM; Griffin DG; Walker V
    J Clin Pathol; 2013 May; 66(5):426-31. PubMed ID: 23454727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a two-stage model system to investigate the mineralization mechanisms involved in idiopathic stone formation: stage 2 in vivo studies of stone growth on biomimetic Randall's plaque.
    O'Kell AL; Lovett AC; Canales BK; Gower LB; Khan SR
    Urolithiasis; 2019 Aug; 47(4):335-346. PubMed ID: 30218116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In idiopathic calcium oxalate stone-formers, unattached stones show evidence of having originated as attached stones on Randall's plaque.
    Miller NL; Williams JC; Evan AP; Bledsoe SB; Coe FL; Worcester EM; Munch LC; Handa SE; Lingeman JE
    BJU Int; 2010 Jan; 105(2):242-5. PubMed ID: 19549258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic and urinary risk factors associated with Randall's papillary plaques.
    Low RK; Stoller ML; Schreiber CK
    J Endourol; 2000 Aug; 14(6):507-10. PubMed ID: 10954308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.